{"protocolSection": {"identificationModule": {"nctId": "NCT01086384", "orgStudyIdInfo": {"id": "106837"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Asthma Exacerbation Study", "officialTitle": "A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects With Asthma"}, "statusModule": {"statusVerifiedDate": "2018-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-02-22"}, "primaryCompletionDateStruct": {"date": "2011-09-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-09-15", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-03-11", "studyFirstSubmitQcDate": "2010-03-11", "studyFirstPostDateStruct": {"date": "2010-03-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-05-30", "resultsFirstSubmitQcDate": "2013-09-05", "resultsFirstPostDateStruct": {"date": "2013-09-11", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2012-07-26", "dispFirstSubmitQcDate": "2012-07-26", "dispFirstPostDateStruct": {"date": "2012-08-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-01-18", "lastUpdatePostDateStruct": {"date": "2018-01-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study will establish the safety as well as demonstrate benefit of the addition of a LABA to an ICS by utilizing an endpoint (time to first severe asthma exacerbation) that informs on both safety and efficacy."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 2020, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Fluticasone furoate/GW642444", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Fluticasone Furoate/GW642444"]}, {"label": "fluticasone furoate", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Fluticasone furoate"]}], "interventions": [{"type": "DRUG", "name": "Fluticasone Furoate/GW642444", "description": "Combination inhaled corticosteroid and long-acting beta2-agonist", "armGroupLabels": ["Fluticasone furoate/GW642444"]}, {"type": "DRUG", "name": "Fluticasone furoate", "description": "Inhaled corticosteroid", "armGroupLabels": ["fluticasone furoate"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With 1 or More Severe Asthma Exacerbations", "description": "Asthma is a medical condition that causes narrowing of the small airways in the lungs. A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Only events deemed by the adjudication committee to be severe asthma exacerbations were used in the analysis of severe asthma exacerbations. The time to the first severe asthma exacerbation was analyzed using a Cox proportional hazards regression model, adjusting for Baseline disease severity (Baseline forced expiratory volume in one second \\[FEV1, maximum amount of air forcefully exhaled in one second\\]), sex, age, and region.", "timeFrame": "Baseline to Follow-up (up to 76 weeks of treatment)"}], "secondaryOutcomes": [{"measure": "Number of Severe Asthma Exacerbations", "description": "A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. A participant may have had one or more exacerbations.", "timeFrame": "Baseline to Follow-up (up to 76 weeks of treatment)"}, {"measure": "Change From Baseline in Evening Pre-dose Trough FEV1 at Week 36", "description": "Evening pre-dose trough (lowest value) forced expiratory volume in one second (FEV1) was measured using spirometry equipment that met or exceeded the minimal performance recommendations of the American Thoracic Society. FEV1 is a measure of the maximum amount of air forcefully exhaled in one second. Change from Baseline in evening pre-dose FEV1 was analyzed using an Analysis of Covariance (ANCOVA) model with effects due to Baseline FEV1, sex, age, region, and treatment. Change from Baseline was calculated as the Week 36 value minus the Baseline value.", "timeFrame": "Baseline and Week 36"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Clinical diagnosis of asthma\n* Reversibility FEV1 of twelve percent or greater and two hundred milliliters and greater approximately ten to forty minutes following two to four inhalations of albuterol\n* FEV1 of fifty to ninety percent of predicted\n* Currently using inhaled corticosteroid therapy\n* History of one or more asthma exacerbations requiring treatment with oral/systemic corticosteroids or emergency department visit or in-patient hospitalization in previous year\n\nExclusion Criteria:\n\n* History of life threatening asthma in previous 5 years (requiring intubation, and/or associated with hypercapnia, hypoxic seizure or respiratory arrest\n* Respiratory infection or oral candidiasis\n* - Uncontrolled disease or clinical abnormality\n* Allergies\n* Taking another investigational medication or prohibited medication", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Mobile", "state": "Alabama", "zip": "36608", "country": "United States", "geoPoint": {"lat": 30.69436, "lon": -88.04305}}, {"facility": "GSK Investigational Site", "city": "Oxford", "state": "Alabama", "zip": "36203", "country": "United States", "geoPoint": {"lat": 33.61427, "lon": -85.83496}}, {"facility": "GSK Investigational Site", "city": "Phoenix", "state": "Arizona", "zip": "85016", "country": "United States", "geoPoint": {"lat": 33.44838, "lon": -112.07404}}, {"facility": "GSK Investigational Site", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "GSK Investigational Site", "city": "Tucson", "state": "Arizona", "zip": "85724-5073", "country": "United States", "geoPoint": {"lat": 32.22174, "lon": -110.92648}}, {"facility": "GSK Investigational Site", "city": "Bell Gardens", "state": "California", "zip": "90201", "country": "United States", "geoPoint": {"lat": 33.96529, "lon": -118.15146}}, {"facility": "GSK Investigational Site", "city": "Fresno", "state": "California", "zip": "93721", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "GSK Investigational Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "GSK Investigational Site", "city": "Long Beach", "state": "California", "zip": "90808", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "GSK Investigational Site", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "GSK Investigational Site", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "GSK Investigational Site", "city": "Napa", "state": "California", "zip": "94558", "country": "United States", "geoPoint": {"lat": 38.29714, "lon": -122.28553}}, {"facility": "GSK Investigational Site", "city": "Rancho Mirage", "state": "California", "zip": "92270", "country": "United States", "geoPoint": {"lat": 33.73974, "lon": -116.41279}}, {"facility": "GSK Investigational Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "GSK Investigational Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "GSK Investigational Site", "city": "Roseville", "state": "California", "zip": "95661", "country": "United States", "geoPoint": {"lat": 38.75212, "lon": -121.28801}}, {"facility": "GSK Investigational Site", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "GSK Investigational Site", "city": "Stockton", "state": "California", "zip": "95207", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "GSK Investigational Site", "city": "Torrance", "state": "California", "zip": "90505", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "GSK Investigational Site", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "GSK Investigational Site", "city": "Englewood", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.64777, "lon": -104.98776}}, {"facility": "GSK Investigational Site", "city": "Cocoa", "state": "Florida", "zip": "32927", "country": "United States", "geoPoint": {"lat": 28.38612, "lon": -80.742}}, {"facility": "GSK Investigational Site", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "GSK Investigational Site", "city": "Valrico", "state": "Florida", "zip": "33596", "country": "United States", "geoPoint": {"lat": 27.93789, "lon": -82.23644}}, {"facility": "GSK Investigational Site", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "GSK Investigational Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "GSK Investigational Site", "city": "Columbus", "state": "Georgia", "zip": "31904", "country": "United States", "geoPoint": {"lat": 32.46098, "lon": -84.98771}}, {"facility": "GSK Investigational Site", "city": "Lawrenceville", "state": "Georgia", "zip": "30046", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "GSK Investigational Site", "city": "Coeur d'Alene", "state": "Idaho", "zip": "83814", "country": "United States", "geoPoint": {"lat": 47.67768, "lon": -116.78047}}, {"facility": "GSK Investigational Site", "city": "River Forest", "state": "Illinois", "zip": "60305", "country": "United States", "geoPoint": {"lat": 41.89781, "lon": -87.81395}}, {"facility": "GSK Investigational Site", "city": "Indianapolis", "state": "Indiana", "zip": "46256", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "GSK Investigational Site", "city": "Hazard", "state": "Kentucky", "zip": "41701", "country": "United States", "geoPoint": {"lat": 37.24954, "lon": -83.19323}}, {"facility": "GSK Investigational Site", "city": "Owensboro", "state": "Kentucky", "zip": "42301", "country": "United States", "geoPoint": {"lat": 37.77422, "lon": -87.11333}}, {"facility": "GSK Investigational Site", "city": "Metairie", "state": "Louisiana", "zip": "70006", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "GSK Investigational Site", "city": "Sunset", "state": "Louisiana", "zip": "70584", "country": "United States", "geoPoint": {"lat": 30.41131, "lon": -92.06845}}, {"facility": "GSK Investigational Site", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "GSK Investigational Site", "city": "Bronx", "state": "New York", "zip": "10461", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "GSK Investigational Site", "city": "Rockville Center", "state": "New York", "zip": "11570", "country": "United States"}, {"facility": "GSK Investigational Site", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Sylvania", "state": "Ohio", "zip": "43560", "country": "United States", "geoPoint": {"lat": 41.71894, "lon": -83.71299}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "GSK Investigational Site", "city": "Eugene", "state": "Oregon", "zip": "97401", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "GSK Investigational Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "GSK Investigational Site", "city": "Collegeville", "state": "Pennsylvania", "zip": "19426", "country": "United States", "geoPoint": {"lat": 40.18566, "lon": -75.45157}}, {"facility": "GSK Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "GSK Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19115", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "GSK Investigational Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15241", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "GSK Investigational Site", "city": "Charleston", "state": "South Carolina", "zip": "29407", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "GSK Investigational Site", "city": "Gaffney", "state": "South Carolina", "zip": "29340", "country": "United States", "geoPoint": {"lat": 35.07179, "lon": -81.64982}}, {"facility": "GSK Investigational Site", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "GSK Investigational Site", "city": "Union", "state": "South Carolina", "zip": "29379", "country": "United States", "geoPoint": {"lat": 34.71541, "lon": -81.62371}}, {"facility": "GSK Investigational Site", "city": "Knoxville", "state": "Tennessee", "zip": "37909", "country": "United States", "geoPoint": {"lat": 35.96064, "lon": -83.92074}}, {"facility": "GSK Investigational Site", "city": "Austin", "state": "Texas", "zip": "78750", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "GSK Investigational Site", "city": "Houston", "state": "Texas", "zip": "77054", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "GSK Investigational Site", "city": "Houston", "state": "Texas", "zip": "77074", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "GSK Investigational Site", "city": "Killeen", "state": "Texas", "zip": "76542", "country": "United States", "geoPoint": {"lat": 31.11712, "lon": -97.7278}}, {"facility": "GSK Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "GSK Investigational Site", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "GSK Investigational Site", "city": "South Burlington", "state": "Vermont", "zip": "05403", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"facility": "GSK Investigational Site", "city": "Bellingham", "state": "Washington", "zip": "98225", "country": "United States", "geoPoint": {"lat": 48.75955, "lon": -122.48822}}, {"facility": "GSK Investigational Site", "city": "La Crosse", "state": "Wisconsin", "zip": "54601", "country": "United States", "geoPoint": {"lat": 43.80136, "lon": -91.23958}}, {"facility": "GSK Investigational Site", "city": "Quilmes", "state": "Buenos Aires", "zip": "B1878FNR", "country": "Argentina", "geoPoint": {"lat": -34.72904, "lon": -58.26374}}, {"facility": "GSK Investigational Site", "city": "Parana", "state": "Entre R\u00edos", "zip": "E3100BHK", "country": "Argentina", "geoPoint": {"lat": -31.73197, "lon": -60.5238}}, {"facility": "GSK Investigational Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000DSR", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "GSK Investigational Site", "city": "Buenos Aires", "zip": "C1424BSF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Buenos Aires", "zip": "C1425BEN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "zip": "C1121ABE", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Mendoza", "zip": "M5500CCG", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "GSK Investigational Site", "city": "Tucuman", "zip": "4000", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "GSK Investigational Site", "city": "Garran", "state": "Australian Capital Territory", "zip": "2606", "country": "Australia", "geoPoint": {"lat": -35.34206, "lon": 149.10846}}, {"facility": "GSK Investigational Site", "city": "Blacktown", "state": "New South Wales", "zip": "2148", "country": "Australia", "geoPoint": {"lat": -33.76667, "lon": 150.91667}}, {"facility": "GSK Investigational Site", "city": "Hornsby", "state": "New South Wales", "zip": "2077", "country": "Australia", "geoPoint": {"lat": -33.70244, "lon": 151.09931}}, {"facility": "GSK Investigational Site", "city": "Auchenflower", "state": "Queensland", "zip": "4066", "country": "Australia", "geoPoint": {"lat": -27.47443, "lon": 152.99213}}, {"facility": "GSK Investigational Site", "city": "Toorak Gardens", "state": "South Australia", "zip": "5065", "country": "Australia", "geoPoint": {"lat": -34.93478, "lon": 138.63639}}, {"facility": "GSK Investigational Site", "city": "Clayton", "state": "Victoria", "zip": "3168", "country": "Australia", "geoPoint": {"lat": -37.91667, "lon": 145.11667}}, {"facility": "GSK Investigational Site", "city": "Deggingen", "state": "Baden-Wuerttemberg", "zip": "73326", "country": "Germany", "geoPoint": {"lat": 48.5971, "lon": 9.71891}}, {"facility": "GSK Investigational Site", "city": "Weinheim", "state": "Baden-Wuerttemberg", "zip": "69469", "country": "Germany", "geoPoint": {"lat": 49.54887, "lon": 8.66697}}, {"facility": "GSK Investigational Site", "city": "Aschaffenburg", "state": "Bayern", "zip": "63739", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "GSK Investigational Site", "city": "Grossheirath", "state": "Bayern", "zip": "96269", "country": "Germany", "geoPoint": {"lat": 50.1763, "lon": 10.95048}}, {"facility": "GSK Investigational Site", "city": "Vilshofen", "state": "Bayern", "zip": "94474", "country": "Germany", "geoPoint": {"lat": 48.62695, "lon": 13.19222}}, {"facility": "GSK Investigational Site", "city": "Cottbus", "state": "Brandenburg", "zip": "03050", "country": "Germany", "geoPoint": {"lat": 51.75769, "lon": 14.32888}}, {"facility": "GSK Investigational Site", "city": "Potsdam", "state": "Brandenburg", "zip": "14469", "country": "Germany", "geoPoint": {"lat": 52.39886, "lon": 13.06566}}, {"facility": "GSK Investigational Site", "city": "Ruedersdorf", "state": "Brandenburg", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Marburg", "state": "Hessen", "zip": "35037", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "GSK Investigational Site", "city": "Bochum", "state": "Nordrhein-Westfalen", "zip": "44787", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"facility": "GSK Investigational Site", "city": "Dortmund", "state": "Nordrhein-Westfalen", "zip": "44263", "country": "Germany", "geoPoint": {"lat": 51.51494, "lon": 7.466}}, {"facility": "GSK Investigational Site", "city": "Essen", "state": "Nordrhein-Westfalen", "zip": "45359", "country": "Germany", "geoPoint": {"lat": 51.45657, "lon": 7.01228}}, {"facility": "GSK Investigational Site", "city": "Gelsenkirchen", "state": "Nordrhein-Westfalen", "zip": "45879", "country": "Germany", "geoPoint": {"lat": 51.50508, "lon": 7.09655}}, {"facility": "GSK Investigational Site", "city": "Goch", "state": "Nordrhein-Westfalen", "zip": "47574", "country": "Germany", "geoPoint": {"lat": 51.67873, "lon": 6.15895}}, {"facility": "GSK Investigational Site", "city": "Solingen", "state": "Nordrhein-Westfalen", "zip": "42651", "country": "Germany", "geoPoint": {"lat": 51.17343, "lon": 7.0845}}, {"facility": "GSK Investigational Site", "city": "Witten", "state": "Nordrhein-Westfalen", "zip": "58452", "country": "Germany", "geoPoint": {"lat": 51.44362, "lon": 7.35258}}, {"facility": "GSK Investigational Site", "city": "Koblenz", "state": "Rheinland-Pfalz", "zip": "56068", "country": "Germany", "geoPoint": {"lat": 50.35357, "lon": 7.57883}}, {"facility": "GSK Investigational Site", "city": "Mainz", "state": "Rheinland-Pfalz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "GSK Investigational Site", "city": "Rhaunen", "state": "Rheinland-Pfalz", "zip": "55624", "country": "Germany", "geoPoint": {"lat": 49.86322, "lon": 7.34232}}, {"facility": "GSK Investigational Site", "city": "Leipzig", "state": "Sachsen", "zip": "04275", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "GSK Investigational Site", "city": "Erfurt", "state": "Thueringen", "zip": "99084", "country": "Germany", "geoPoint": {"lat": 50.9787, "lon": 11.03283}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "13086", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "20357", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "22299", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "22335", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "22767", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Fukuoka", "zip": "802-0052", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "GSK Investigational Site", "city": "Fukuoka", "zip": "832-0059", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "GSK Investigational Site", "city": "Hokkaido", "zip": "064-0801", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "GSK Investigational Site", "city": "Kagoshima", "zip": "890-0064", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "GSK Investigational Site", "city": "Kagoshima", "zip": "892-0844", "country": "Japan", "geoPoint": {"lat": 31.56667, "lon": 130.55}}, {"facility": "GSK Investigational Site", "city": "Kanagawa", "zip": "252-0143", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "GSK Investigational Site", "city": "Kyoto", "zip": "601-8206", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "GSK Investigational Site", "city": "Kyoto", "zip": "612-0026", "country": "Japan", "geoPoint": {"lat": 35.02107, "lon": 135.75385}}, {"facility": "GSK Investigational Site", "city": "Saitama", "zip": "343-0808", "country": "Japan", "geoPoint": {"lat": 35.90807, "lon": 139.65657}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "113-0031", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "153-0051", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "187-0024", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "190-0013", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "204-0021", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Guadalajara", "state": "Jalisco", "zip": "44100", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "GSK Investigational Site", "city": "Zapopan", "state": "Jalisco", "zip": "45040", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "GSK Investigational Site", "city": "Monterrey NL", "state": "Nuevo Le\u00f3n", "zip": "64718", "country": "Mexico"}, {"facility": "GSK Investigational Site", "city": "Villahermosa", "state": "Tabasco", "zip": "86100", "country": "Mexico", "geoPoint": {"lat": 17.98689, "lon": -92.93028}}, {"facility": "GSK Investigational Site", "city": "Mexico city", "zip": "04530", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "GSK Investigational Site", "city": "Mexico City", "zip": "07760", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "GSK Investigational Site", "city": "Iloilo City", "zip": "5000", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "GSK Investigational Site", "city": "Lipa City", "zip": "4217", "country": "Philippines", "geoPoint": {"lat": 13.9411, "lon": 121.1631}}, {"facility": "GSK Investigational Site", "city": "Marilao, Bulacan", "zip": "3019", "country": "Philippines"}, {"facility": "GSK Investigational Site", "city": "Quezon City", "zip": "1101", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "GSK Investigational Site", "city": "Quezon City", "zip": "1109", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "GSK Investigational Site", "city": "Bydgoszcz", "zip": "85-681", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "GSK Investigational Site", "city": "Debica", "zip": "39-200", "country": "Poland", "geoPoint": {"lat": 50.05146, "lon": 21.41141}}, {"facility": "GSK Investigational Site", "city": "Gdansk", "zip": "80-169", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"facility": "GSK Investigational Site", "city": "Kielce", "country": "Poland", "geoPoint": {"lat": 50.87033, "lon": 20.62752}}, {"facility": "GSK Investigational Site", "city": "Koszalin", "country": "Poland", "geoPoint": {"lat": 54.19438, "lon": 16.17222}}, {"facility": "GSK Investigational Site", "city": "Krakow", "zip": "31-159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "GSK Investigational Site", "city": "Lublin", "zip": "20-089", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "GSK Investigational Site", "city": "Lublin", "zip": "20-954", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "GSK Investigational Site", "city": "Olsztyn", "zip": "10-357", "country": "Poland", "geoPoint": {"lat": 53.77995, "lon": 20.49416}}, {"facility": "GSK Investigational Site", "city": "Poznan", "zip": "60-214", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "GSK Investigational Site", "city": "Poznan", "zip": "60-693", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "GSK Investigational Site", "city": "Rzeszow", "country": "Poland", "geoPoint": {"lat": 50.04132, "lon": 21.99901}}, {"facility": "GSK Investigational Site", "city": "Wolomin", "zip": "05-200", "country": "Poland", "geoPoint": {"lat": 52.34006, "lon": 21.24207}}, {"facility": "GSK Investigational Site", "city": "Wroclaw", "zip": "50-445", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "GSK Investigational Site", "city": "Wroclaw", "zip": "54-239", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "GSK Investigational Site", "city": "Bucharest", "zip": "020674", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "GSK Investigational Site", "city": "Bucharest", "zip": "050159", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "GSK Investigational Site", "city": "Craiova", "zip": "200341", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"facility": "GSK Investigational Site", "city": "Deva", "zip": "330084", "country": "Romania", "geoPoint": {"lat": 45.88333, "lon": 22.9}}, {"facility": "GSK Investigational Site", "city": "Pitesti", "zip": "110084", "country": "Romania", "geoPoint": {"lat": 44.85, "lon": 24.86667}}, {"facility": "GSK Investigational Site", "city": "Sibiu", "zip": "550166", "country": "Romania", "geoPoint": {"lat": 45.8, "lon": 24.15}}, {"facility": "GSK Investigational Site", "city": "Barnaul", "zip": "656 045", "country": "Russian Federation", "geoPoint": {"lat": 53.36056, "lon": 83.76361}}, {"facility": "GSK Investigational Site", "city": "Blagoveshchensk", "zip": "675000", "country": "Russian Federation", "geoPoint": {"lat": 50.27961, "lon": 127.5405}}, {"facility": "GSK Investigational Site", "city": "Chelyabinsk", "zip": "454106", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "GSK Investigational Site", "city": "Kazan", "zip": "420015", "country": "Russian Federation", "geoPoint": {"lat": 55.78874, "lon": 49.12214}}, {"facility": "GSK Investigational Site", "city": "Krasnodar", "country": "Russian Federation", "geoPoint": {"lat": 45.04484, "lon": 38.97603}}, {"facility": "GSK Investigational Site", "city": "Novosibirsk", "zip": "630047", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "GSK Investigational Site", "city": "Novosibirsk", "zip": "630087", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "GSK Investigational Site", "city": "Penza", "zip": "440067", "country": "Russian Federation", "geoPoint": {"lat": 53.20066, "lon": 45.00464}}, {"facility": "GSK Investigational Site", "city": "Perm", "zip": "614077", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "GSK Investigational Site", "city": "Pyatigorsk", "zip": "357538", "country": "Russian Federation", "geoPoint": {"lat": 44.04861, "lon": 43.05944}}, {"facility": "GSK Investigational Site", "city": "Saint-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "Saratov", "zip": "410028", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "GSK Investigational Site", "city": "St. Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "Tomsk", "zip": "634001", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"facility": "GSK Investigational Site", "city": "Volgodonsk", "zip": "347381", "country": "Russian Federation", "geoPoint": {"lat": 47.51361, "lon": 42.15139}}, {"facility": "GSK Investigational Site", "city": "Voronezh", "zip": "394018", "country": "Russian Federation", "geoPoint": {"lat": 51.67204, "lon": 39.1843}}, {"facility": "GSK Investigational Site", "city": "Dnipropetrovsk", "zip": "49051", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"facility": "GSK Investigational Site", "city": "Donetsk", "zip": "83017", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "02091", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "02660", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03038", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03115", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "04050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Kyiv", "zip": "04201", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Simferopol", "zip": "95034", "country": "Ukraine", "geoPoint": {"lat": 44.95719, "lon": 34.11079}}, {"facility": "GSK Investigational Site", "city": "Vinnytsia", "zip": "21029", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "GSK Investigational Site", "city": "Yalta", "zip": "98603", "country": "Ukraine", "geoPoint": {"lat": 44.50218, "lon": 34.16624}}, {"facility": "GSK Investigational Site", "city": "Zaporizhia", "zip": "69063", "country": "Ukraine", "geoPoint": {"lat": 47.82289, "lon": 35.19031}}, {"facility": "GSK Investigational Site", "city": "Zaporizhia", "zip": "69076", "country": "Ukraine", "geoPoint": {"lat": 47.82289, "lon": 35.19031}}]}, "referencesModule": {"references": [{"pmid": "27881132", "type": "DERIVED", "citation": "O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x."}, {"pmid": "26704701", "type": "DERIVED", "citation": "Gross AS, Goldfrad C, Hozawa S, James MH, Clifton CS, Sugiyama Y, Jacques L. Ethnic sensitivity assessment of fluticasone furoate/vilanterol in East Asian asthma patients from randomized double-blind multicentre Phase IIb/III trials. BMC Pulm Med. 2015 Dec 24;15:165. doi: 10.1186/s12890-015-0159-z."}, {"pmid": "24253831", "type": "DERIVED", "citation": "Bateman ED, O'Byrne PM, Busse WW, Lotvall J, Bleecker ER, Andersen L, Jacques L, Frith L, Lim J, Woodcock A. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014 Apr;69(4):312-9. doi: 10.1136/thoraxjnl-2013-203600. Epub 2013 Nov 19."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "106837", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106837", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106837", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106837", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106837", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106837", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "106837", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants (par.) who met all entry criteria at Screening entered a 2-week Run-in Period for completion of Baseline safety evaluations and to obtain Baseline measures of asthma status. Participants who met continuation criteria at the end of the Run-in Period were randomized to receive study treatment.", "groups": [{"id": "FG000", "title": "FP 250 \u00b5g/ICS", "description": "Japanese participants using fluticasone propionate (FP)/salmeterol 250/50 micrograms (\u00b5g) twice daily received open-label FP 250 \u00b5g to ensure they continued their inhaled corticosteroid (ICS) therapy at a fixed dose during the 2-week Run-in Period. All other participants continued to use their current ICS therapy at a fixed dose during the 2-week Run-in Period. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Run-in Period."}, {"id": "FG001", "title": "FF 100 \u00b5g", "description": "Participants received fluticasone furoate (FF) 100 microgram (\u00b5g) inhalation powder via a dry powder inhaler (DPI) once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}, {"id": "FG002", "title": "FF/VI 100/25 \u00b5g", "description": "Participants received FF/vilanterol (VI) 100/25 \u00b5g inhalation powder via a DPI once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}], "periods": [{"title": "2-week Run-in Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2183"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2020"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "163"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Study Closed/Terminated", "reasons": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Continuation Criteria Not Met", "reasons": [{"groupId": "FG000", "numSubjects": "92"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Randomized in Error", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1011"}, {"groupId": "FG002", "numSubjects": "1009"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "863"}, {"groupId": "FG002", "numSubjects": "885"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "148"}, {"groupId": "FG002", "numSubjects": "124"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "53"}, {"groupId": "FG002", "numSubjects": "55"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "26"}, {"groupId": "FG002", "numSubjects": "17"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "22"}, {"groupId": "FG002", "numSubjects": "13"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "19"}, {"groupId": "FG002", "numSubjects": "15"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "11"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "6"}]}, {"type": "Study Closed/Terminated", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "8"}]}, {"type": "Protocol-Defined Stopping Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Received Treatment in Error", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "FF 100 \u00b5g", "description": "Participants received fluticasone furoate (FF) 100 microgram (\u00b5g) inhalation powder via a dry powder inhaler (DPI) once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}, {"id": "BG001", "title": "FF/VI 100/25 \u00b5g", "description": "Participants received FF/vilanterol (VI) 100/25 \u00b5g inhalation powder via a DPI once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1010"}, {"groupId": "BG001", "value": "1009"}, {"groupId": "BG002", "value": "2019"}]}], "measures": [{"title": "Age, Continuous", "description": "Baseline characteristic data were collected in members of the Intent-to-Treat Population, comprised of all participants randomized to treatment who received at least one dose of study medication.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.3", "spread": "16.82"}, {"groupId": "BG001", "value": "41.1", "spread": "17.10"}, {"groupId": "BG002", "value": "41.7", "spread": "16.96"}]}]}]}, {"title": "Sex: Female, Male", "description": "Baseline characteristic data were collected in members of the Intent-to-Treat Population, comprised of all participants randomized to treatment who received at least one dose of study medication.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "689"}, {"groupId": "BG001", "value": "661"}, {"groupId": "BG002", "value": "1350"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "321"}, {"groupId": "BG001", "value": "348"}, {"groupId": "BG002", "value": "669"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "Baseline characteristic data were collected in members of the Intent-to-Treat Population, comprised of all participants randomized to treatment who received at least one dose of study medication.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "47"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "87"}]}]}, {"title": "American Indian or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "13"}]}]}, {"title": "Asian - Central/South Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Asian - East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Asian - Japanese Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "62"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "157"}]}]}, {"title": "Native Hawaiian or other Pacific Islander", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "7"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "738"}, {"groupId": "BG001", "value": "738"}, {"groupId": "BG002", "value": "1476"}]}]}, {"title": "Mixed Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "104"}, {"groupId": "BG001", "value": "108"}, {"groupId": "BG002", "value": "212"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With 1 or More Severe Asthma Exacerbations", "description": "Asthma is a medical condition that causes narrowing of the small airways in the lungs. A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. Only events deemed by the adjudication committee to be severe asthma exacerbations were used in the analysis of severe asthma exacerbations. The time to the first severe asthma exacerbation was analyzed using a Cox proportional hazards regression model, adjusting for Baseline disease severity (Baseline forced expiratory volume in one second \\[FEV1, maximum amount of air forcefully exhaled in one second\\]), sex, age, and region.", "populationDescription": "Intent-to-Treat (ITT) Population: all participants randomized to treatment who received at least one dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline to Follow-up (up to 76 weeks of treatment)", "groups": [{"id": "OG000", "title": "FF 100 \u00b5g", "description": "Participants received fluticasone furoate (FF) 100 microgram (\u00b5g) inhalation powder via a dry powder inhaler (DPI) once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 100/25 \u00b5g", "description": "Participants received FF/vilanterol (VI) 100/25 \u00b5g inhalation powder via a DPI once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1010"}, {"groupId": "OG001", "value": "1009"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "154"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "paramType": "Regression Cox", "paramValue": "0.795", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.642", "ciUpperLimit": "0.985", "estimateComment": "The estimated values is the Hazard ratio obtained from the Cox regression analysis for FF/VI 100/25 \u00b5g versus FF 100 \u00b5g, adjusted for an interim analysis."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.036", "pValueComment": "P-value for the Hazard ratio obtained from the Cox regression analysis for FF/VI 100/25 \u00b5g versus FF 100 \u00b5g, adjusted for an interim analysis.", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "15.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "13.5", "ciUpperLimit": "18.2", "estimateComment": "The estimated value represents the adjusted probability of 1 or more severe asthma exacerbations by Week 52 for FF 100 \u00b5g. Cox Proportional Hazards Model estimate at mean Baseline FEV1, age, and proportional coefficients for sex and region."}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.036", "pValueComment": "P-value for the Hazard ratio obtained from the Cox regression analysis for FF/VI 100/25 \u00b5g versus FF 100 \u00b5g, adjusted for an interim analysis.", "statisticalMethod": "Regression, Cox", "paramType": "Cox Proportional Hazard", "paramValue": "12.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "10.7", "ciUpperLimit": "14.9", "estimateComment": "The estimated value represents the adjusted probability of 1 or more severe asthma exacerbations by Week 52 for FF/VI 100/25 \u00b5g. Cox Proportional Hazards Model estimate at mean Baseline FEV1, age, and proportional coefficients for sex and region."}]}, {"type": "SECONDARY", "title": "Number of Severe Asthma Exacerbations", "description": "A severe asthma exacerbation is defined as a deterioration of asthma requiring the use of systemic corticosteroids (tablets, suspension, or injection) for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids. A participant may have had one or more exacerbations.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Severe asthma exacerbations", "timeFrame": "Baseline to Follow-up (up to 76 weeks of treatment)", "groups": [{"id": "OG000", "title": "FF 100 \u00b5g", "description": "Participants received fluticasone furoate (FF) 100 microgram (\u00b5g) inhalation powder via a dry powder inhaler (DPI) once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 100/25 \u00b5g", "description": "Participants received FF/vilanterol (VI) 100/25 \u00b5g inhalation powder via a DPI once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1010"}, {"groupId": "OG001", "value": "1009"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "271"}, {"groupId": "OG001", "value": "200"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Evening Pre-dose Trough FEV1 at Week 36", "description": "Evening pre-dose trough (lowest value) forced expiratory volume in one second (FEV1) was measured using spirometry equipment that met or exceeded the minimal performance recommendations of the American Thoracic Society. FEV1 is a measure of the maximum amount of air forcefully exhaled in one second. Change from Baseline in evening pre-dose FEV1 was analyzed using an Analysis of Covariance (ANCOVA) model with effects due to Baseline FEV1, sex, age, region, and treatment. Change from Baseline was calculated as the Week 36 value minus the Baseline value.", "populationDescription": "ITT Population. Only those participants available at the indicated time point (Week 36) were analyzed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Liters", "timeFrame": "Baseline and Week 36", "groups": [{"id": "OG000", "title": "FF 100 \u00b5g", "description": "Participants received fluticasone furoate (FF) 100 microgram (\u00b5g) inhalation powder via a dry powder inhaler (DPI) once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}, {"id": "OG001", "title": "FF/VI 100/25 \u00b5g", "description": "Participants received FF/vilanterol (VI) 100/25 \u00b5g inhalation powder via a DPI once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "902"}, {"groupId": "OG001", "value": "926"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.265", "spread": "0.014"}, {"groupId": "OG001", "value": "0.348", "spread": "0.014"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "description": "Serious adverse events (SAEs) and non-serious AEs are reported for members of the ITT Population, comprised of all participants randomized to treatment who received at least one dose of study medication.", "eventGroups": [{"id": "EG000", "title": "FF 100 \u00b5g", "description": "Participants received fluticasone furoate (FF) 100 microgram (\u00b5g) inhalation powder via a dry powder inhaler (DPI) once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.", "seriousNumAffected": 29, "seriousNumAtRisk": 1010, "otherNumAffected": 479, "otherNumAtRisk": 1010}, {"id": "EG001", "title": "FF/VI 100/25 \u00b5g", "description": "Participants received FF/vilanterol (VI) 100/25 \u00b5g inhalation powder via a DPI once daily in the evening. Short-acting beta2-agonist inhalation aerosol (albuterol/salbutamol) was provided to be used as needed for symptomatic relief of asthma symptoms during the Treatment Period.", "seriousNumAffected": 41, "seriousNumAtRisk": 1009, "otherNumAffected": 467, "otherNumAtRisk": 1009}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 1009}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Pleurisy", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 1009}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Bronchitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Chronic sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Labyrinthitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Lobar pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Meningitis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Skin infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Subcutaneous abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Tracheobronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Metastases to lung", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Osteochondroma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Renal cancer stage I", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Tachyarrthmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Limb traumatic amputation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Upper limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Intervertebral disc degeneration", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Diabetic microangiopathy", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Anal fistula", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Hydrocholecystis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Fear", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Dysfunctional uterine bleeding", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Dermatitis allergic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 1009}]}, {"term": "Deafness unilateral", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Anaphylactic reaction", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}, {"term": "Diabetic foot", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 1009}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 131, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 155, "numAtRisk": 1009}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 93, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 73, "numAtRisk": 1009}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 74, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 59, "numAtRisk": 1009}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 50, "numAtRisk": 1009}]}, {"term": "Sinusitus", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 42, "numAtRisk": 1009}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 41, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 29, "numAtRisk": 1009}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 179, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 188, "numAtRisk": 1009}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 64, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 55, "numAtRisk": 1009}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 55, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 41, "numAtRisk": 1009}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 39, "numAtRisk": 1009}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 26, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 33, "numAtRisk": 1009}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 40, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 41, "numAtRisk": 1009}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 1010}, {"groupId": "EG001", "numAffected": 36, "numAtRisk": 1009}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Clinic visit", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}